

# CLIA & Individualized Quality Control Plan (IQCP)

*Judith Yost*

*Director*

*Division of Laboratory Services*



# Objectives

- Provide Background & History of CLIA Quality Control
- Describe the Development of IQCP
- Present an Overview of Policies and Interpretive Guidelines related to IQCP
- Describe the Implementation Plan for Individualized Quality Control Plan(IQCP)
  - Education & Transition Period

# In the Beginning.....



# Quality Control Milestones.....



# How does IQCP affect labs?

- Applies to CMS-certified non-waived labs
- Labs are already doing many of these activities, it's just not formalized
- EQC will no longer be acceptable and will be removed from the IGs
- IQCP does not have the same requirements as EQC

# EQC vs. IQCP

EQC	IQCP
Transitional	Updated Solution
Standardized	Customizable
Rigid	Flexible
Narrow scope/Limited regulations Limited specialties	Broader scope/More regulations All but Path
Analytic	Pre→Post Analytic
Requires Internal QC Decreases External QC	Does Not Require Internal QC May/may not decrease QC

# Individualized Quality Control Plan (IQCP)

## CLIA

- ✓ **Customizes** QC Plan for each test in its unique environment
- ✓ **Optimizes** use of electronic/integrated controls
- ✓ **Offers** laboratories **flexibility** in achieving QC compliance
- ✓ **Adaptable** for future advancements in technology
- ✓ **Incorporates** other sources of Quality Information
- ✓ **Strengthens** Manufacturer/Laboratory partnerships
- ✓ **Formalizes** risk management data already maintained within the laboratory
- ✓ **Provides** equivalent quality testing to meet the CLIA QC regulations



# The road to IQCP



# Creating IQCP



# IQCP Planning Team

- CMS convened a planning team in 2011 to oversee the implementation of IQCP
- Team mbrs include CO, RO & former deputy div dir. w/ expertise in CLIA & lab medicine
- Planning team instituted WG's to simultaneously accomplish multiple tasks

**RO & SA Training**

**Communications**

**Interpretive Guidelines**

**AO/ES re-approvals**

**Education Outreach**



# Individualized Quality Control Plan

## Policies & Regulations

# The Foundations of IQCP

- Includes key concepts from CLSI EP-23, *“Laboratory Quality Control Based on Risk Management”*
- IQCP is not EP-23
- Labs are not required to incorporate EP-23

# Where do we get our authority?

## 493.1250 Condition: Analytic Systems

- HHS is permitted to approve a procedure which provides equivalent quality testing to meet the Analytic Systems requirements in 493.1251 – 493.1283

# How is IQCP enforceable?

- IQCP is not a regulation, however...
- IQCP will be an enforceable procedure for equivalent quality testing once published in Appendix C of the State Operations Manual
- EQC will no longer be acceptable and will be removed from the IGs

# Mandatory vs. Voluntary

- IQCP is voluntary for laboratories
- Current CLIA control “default” regulations continue to be in effect
- EQC will be discontinued and will no longer be an acceptable QC option under CLIA

# Will IQCP reduce QC?

IQCP is not intended to necessarily reduce QC requirements, but it is intended to ensure effective QC for each laboratory and the tests it performs.

# IQCP Facts

- Existing CLIA QC & quality system concepts won't change
- No regulations will change!
- State and local regulations still apply
- Lab director will continue to have overall responsibility for QCP

# Laboratory Director Responsibilities

The LD is responsible for:

- Accurate and reliable test results that are appropriate for patient care
- Ensuring that IQCP meets the requirements as set forth in IQCP Interpretive Guidelines
- Signing and dating the QCP when implemented and updated.

# Delegation of Duties by the LD

The LD may assign in writing:

- The responsibility for establishing IQCP as part of the laboratory's overall QC program to the TC/TS
- Specific portions of IQCP tasks to other qualified laboratory employees

# Grandfathering of Current Systems

- No grandfathering for current systems using EQC
- However, historical data may be used in the development of an IQCP
- At the end of the Education & Transition Period, all existing and new test systems must comply with IQCP or “default” CLIA regulations

# Manufacturer's Instructions

- Laboratories performing non-waived tests must follow all manufacturers instructions
- When the manufacturer's instructions for QC are absent or less stringent than the “default” CLIA control procedures...
  - the laboratory must choose to develop an IQCP or follow CLIA QC regulations

# Minimum QC Frequency

- CLIA will not set a minimum QC frequency for labs performing IQCP
- However...
  - Performing no QC is unacceptable
  - QC frequency can not be less than the manufacturer's instructions
  - The RA & lab's data must support the QC frequency

# Specialties/Subspecialties

All CLIA specialties/subspecialties will be included in IQCP, except...

- Pathology
- Histopathology
- Oral Pathology
- Cytology

# How do the regulations relate to IQCP?

- All CLIA regulations remain in force and must be followed
- Only the eligible regulations identified in the following table(s) may be considered with IQCP
- Any IQCP eligible regulation that the lab chooses to replace with IQCP must be supported in the RA



Let's take a closer look....

**Table 1: Eligibility for IQCP**

<b>CLIA Specialty/ Subspecialty</b>	<b>Eligible for IQCP?</b>	<b>General Regulations Eligible for IQCP</b>	<b>Specialty/Subspecialty Regulations Eligible for IQCP</b>	<b>Specialty/ Subspecialty Regulations NOT Eligible for IQCP</b>
Bacteriology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1261	N/A
Mycobacteriology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1262	N/A
Mycology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1263	N/A
Parasitology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1264	N/A
Virology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1265	N/A
Syphilis Serology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A
General Immunology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A

**Table 1: Eligibility for IQCP**

<b>CLIA Specialty/ Subspecialty</b>	<b>Eligible for IQCP?</b>	<b>General Regulations Eligible for IQCP</b>	<b>Specialty/Subspecialty Regulations Eligible for IQCP</b>	<b>Specialty/ Subspecialty Regulations NOT Eligible for IQCP</b>
Routine Chemistry	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1267(b),(c)	§493.1267(a), (d)
Urinalysis	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A
Endocrinology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A
Toxicology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A
Hematology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1269	N/A
Immunohematology	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	§493.1271
Clinical Cytogenetics	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	§493.1276

**Table 1: Eligibility for IQCP**

<b>CLIA Specialty/ Subspecialty</b>	<b>Eligible for IQCP?</b>	<b>General Regulations Eligible for IQCP</b>	<b>Specialty/Subspecialty Regulations Eligible for IQCP</b>	<b>Specialty/ Subspecialty Regulations NOT Eligible for IQCP</b>
Radiobioassay	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	N/A	N/A
Histocompatibility	Yes	§493.1256(d)(3)-(5) §493.1256(e)(1)-(4)	§493.1278(b)(6), (c), (d)(6), (e)(3)	§493.1278(a), (b)(1-5),(d)(1-5), (d)(7), (e)(1-2), (f),(g)
Pathology	No	None (Not eligible for IQCP)	N/A	N/A
Histopathology	No	None (Not eligible for IQCP)	N/A	N/A
Oral Pathology	No	None (Not eligible for IQCP)	N/A	N/A
Cytology	No	None (Not eligible for IQCP)	N/A	N/A

# Provider Performed Microscopy (PPM) procedures

- Definition of a PPM
- Is IQCP applicable to PPM procedures?
- Application of IQCP is test dependent
  - Reagents
  - Stains
- All CLIA regulations must continue to be followed

# Interpretive Guidelines

## Individualized Quality Control Plan



# Individualized Quality Control Plan



# Interpretive Guidelines

- IQCP
  - Introduction
  - Lab Director Responsibilities
  - Regulatory Considerations
  - RA
  - QCP
  - QA


# Risk Assessment - Definition

Risk assessment is the identification and evaluation of potential failures and sources of errors in a testing process.  
*(Interpretive Guidelines, Risk Assessment Section)*

# Risk Assessment

- Identify and evaluate risks
- Risks are potential failures and sources of error that can impact the accuracy and precision of test results
- Risk assessment is the first step in risk management

# Risk Assessment in IQCP



# Risk Assessment in IQCP: Components

## 5 Required Components:

- Specimen
- Environment
- Reagent
- Test system
- Testing personnel

# Risk Assessment in IQCP: Entire Testing Process

Must consider the entire testing process:

- Pre-analytic
- Analytic
- Post-analytic

# Risk Assessment: I did it my way!

- The risk assessment for any given test system may look very different in different laboratories
- For example, the same risk may be assigned to different components by different laboratories

# Risk Assessment in IQCP: Data

## Data requirements

- Laboratory's own data required
- Can be new data or historical

# Laboratory: Risk Evaluation

- The laboratory evaluates the risks
- There are many methods to evaluate risks
- IQCP does not mandate any specific method of risk evaluation
- The laboratory must provide documented evidence of the risk assessment

# Laboratory Risk Evaluation

The laboratory director must ensure that the risk assessment considers both the CLIA requirements for accurate test results and the responsibility for ensuring that test result quality is adequate for patient care.

# Linking the RA to QCP

After the lab has identified the sources of potential failures and errors for a testing process and evaluated the frequency and impact of those failures and errors, the resulting RA is used to develop the Quality Control Plan (QCP). (*Interpretive Guidelines, Risk Assessment Section*)

# Quality Control Plan - Definition

A QCP is a document that describes the practices, resources, and procedures to control the quality of a particular test process. (*Interpretive Guidelines, Quality Control Plan Section*)

# “I” Means Individualized

Customized/individualized QCP based on lab's specific circumstances (type of testing (subspecialty/specialty), test volume, availability of clinical info, test complexity, patient population & environment.

# The QCP Must...

- Monitor over time the accuracy and precision of test performance
- Include the number, type, and frequency of QC
- Define criteria for acceptability of QC

# Other information to consider

If indicated by the evaluation of the risk assessment, the QCP may also include

- electronic controls,
- procedural controls,
- training and
- competency assessment,
- other specified quality control activities

# Quality Assessment

- The laboratory must establish a review system for the on-going monitoring of the effectiveness of their QCP.
- The monitoring should include at least the following: testing personnel, environment, specimens, reagents, and test system.  
*(Interpretive Guidelines, Quality Control Plan Section)*

# QA

When the laboratory discovers a testing process failure, the laboratory must conduct and document an investigation to identify the cause of the failure, its impact on patient care, and make appropriate modifications to their QCP

# QA

If necessary, the laboratory must update the risk assessment with the new information and modify the QCP

# Education and Transition Period

Look closer...



# Before Education & Transition Period for IQCP – CLIA Surveyors

- Principles of Risk Management at each division meeting
- National Surveyor Training on IQCP – November 18 – 22, 2013
- **S&C 13-54-CLIA** letter released August 16, 2013 provides information, timelines and policy decisions.

# Timeline



**Begins: January 1, 2014**

**Ends: January 1, 2016**

# Preparing for Implementation of IQCP - Laboratories

- IQCP Education & Transition (E/T) Period
  - Two years long
  - Learn about IQCP & ask questions
  - Make transition plans
  - Begin to implement qc option if MI QC frequency is less than current CLIA QC regulations

# Three Options for Compliance during E&T period....

- Follow the CLIA regulatory QC requirements as written
- Continue to follow the EQC procedures as described in the current IGs
- Implement IQCP as described in S&C-13-54-CLIA

# Timeline for Surveyors

- January 1, 2014: Surveyors will survey according to instructions for Education and Transition Period (S&C Letter 13-54-CLIA)
- January 1, 2016: Surveyors will survey for compliance with CLIA QC regulations or IQCP

# Timeline for Laboratories

- January 1, 2014: Laboratories may use CLIA QC regulations, EQC, or IQCP
- January 1, 2016: Laboratories must follow CLIA QC regulations or IQCP

## During Educational and Transition (E/T) Period

- If a laboratory opts to use IQCP....
  - Surveys will be educational for labs implementing IQCP, all other regulations must be met
  - Surveyors are directed to use a “Dear Laboratory Director letter” to report any findings for IQCP related issues.

# Education & Transition Period for IQCP

- No control procedure regulatory citations will be issued prior to the end of the education & transition period unless serious test quality problems are found
- If Immediate Jeopardy is identified, deficiencies will be cited.

# End of the Education and Transition Period

- The CLIA Interpretive Guidelines will be revised
  - EQC will be REMOVED
  - IQCP will be INSERTED

## After: E/T Period vs Implementation

- Implementation of IQCP
  - After January 1, 2016
  - The lab will have IQCP or default QC regulations
  - All new and existing test systems must be in compliance

# Education & Transition Period for IQCP

All questions regarding IQCP may be directed to our electronic mailbox

[IQCP@cms.hhs.gov](mailto:IQCP@cms.hhs.gov)

# Education & Transition Period for IQCP

- CMS has solicited accrediting orgs (AO) to determine their interest in IQCP
- Adoption of IQCP “requirements” in AO/ES programs is voluntary
- Accredited labs must continue to meet their accrediting org.’s QC standards

# To summarize.....

- Once effective, IQCP will supersede the current EQC policy
- Existing CLIA QC & QS concepts won't change
- No regulations will change!
- Minimally, labs must follow mfr's. instructions
- Lab director has overall responsibility for QCP

# To summarize.....

- IQCP Interpretive Guidelines...
  - Introduction
  - Lab Director Responsibilities
  - Regulatory Considerations
  - RA
  - QCP
  - QA

# To summarize.....

- Education & transition period for labs before IQCP is fully effective
  - Begins: January 1, 2014**
  - Ends: January 1, 2016**
- Info & Guidance on IQCP can be found at..

[www.cms.hhs.gov/clia/](http://www.cms.hhs.gov/clia/)

# Questions about IQCP?

All questions regarding IQCP may be directed to our electronic mailbox

[IQCP@cms.hhs.gov](mailto:IQCP@cms.hhs.gov)

# CLIA website - IQCP

Individualized Quality Control Plan (IQCP) - Centers for Medicare & Medicaid Services - Windows Internet Explorer

Home | About CMS | Newsroom Center | FAQs | Archive | Share | Help | Email | Print

**CMS.gov**  
Centers for Medicare & Medicaid Services

Learn about [your healthcare options](#)

Medicare | Medicaid/CHIP | Medicare-Medicaid Coordination | Private Insurance | Innovation Center | Regulations and Guidance | Research, Statistics, Data and Systems | Outreach and Education

Home > Regulations and Guidance > Clinical Laboratory Improvement Amendments (CLIA) > Individualized Quality Control Plan (IQCP)

### Clinical Laboratory Improvement Amendments (CLIA)

[How to Apply for a CLIA Certificate, Including International Laboratories](#)

[State Agency & Regional Office](#)

[CLIA Contacts](#)  
(State Agency & Regional Office CLIA Contacts)

[Accreditation](#)

[Organizations/Exempt States](#)

[Categorization of Tests](#)

[Certificate of Waiver Laboratory Project](#)

[Certification Boards for Laboratory Directors of High Complexity Testing](#)

[CLIA Brochures](#)

[CLIA Regulations and Federal](#)

### Individualized Quality Control Plan (IQCP)

The "Individualized Quality Control Plan" (IQCP) is the Clinical Laboratory Improvement Amendments (CLIA) Quality Control (QC) policy currently under development as an alternate QC option allowed by 42CFR493.1250. The guidance and concepts for IQCP are a formal representation and compilation of many things laboratories already do to ensure quality test results. IQCP permits the laboratory to customize its QC plan according to test method and use, environment, and personnel competency while providing for equivalent quality testing.

Refer to the downloads and the related links section below for the following information:

- CLIA Individualized Quality Control Plan (IQCP) benefits
- Initial Plans and Policy Implementation for Clinical and Laboratory Standards Institute (CLSI) Evaluation Protocol-23 (EP), 'Laboratory Quality Control Based on Risk Management', as Clinical Laboratory Improvement Amendment (CLIA) Quality Control (QC) Policy, file: CMS1253857;
- Implementing the Individualized Quality Control Plan (IQCP) for Clinical Laboratory Improvement Amendments (CLIA), file: CMS1256877; and
- Individualized Quality Control Plan (IQCP): A New Quality Control (QC) Option, file: Survey and Cert Letter 13-54.

Any questions about IQCP should be forwarded to [IQCP@cms.hhs.gov](mailto:IQCP@cms.hhs.gov).

### Downloads

2013.08.23\_IQCP Ve... | Final\_Surv for Comp... | Inbox - Archive Folde... | FW: IQCP PPs, Part 2... | FW: IQCP Training PP... | FW: IQCP PPs, The E...

2:47 PM 08/29/2013

[http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Individualized\\_Quality\\_Control\\_Plan\\_IQCP.html](http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Individualized_Quality_Control_Plan_IQCP.html)

# Where to Obtain Information

## CMS/CLIA Web site:

[www.cms.hhs.gov/clia/](http://www.cms.hhs.gov/clia/)

S&C: 13-54-CLIA

<http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Downloads/Survey-and-Cert-Letter-13-54.pdf>

## CMS CLIA Central Office:

410-786-3531

## Judy Yost's email:

Judith.yost@cms.hhs.gov

## IOCP Link:

IOCP@cms.hhs.gov



**THE END!!**

**Thank You!!!**